Compare Enovix Corporation (ENVX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Revvity Inc — how do they compare? Enovix Corporation trades at $2.41 (market cap $549.72M), while Revvity Inc trades at $154.68 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 30.9× Enovix Corporation's market cap, and Revvity Inc pays a 0.18% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Revvity Inc for 12 Days on average.
| ENVX | RVTY | |
|---|---|---|
Market Cap | $549.72M | $16.98B |
Volume | 6,635,687 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $13.19 | $157.36 |
52-Week Low | $2.50 | $82.26 |
Typical Hold Time | 11 Days | 12 Days |
Enterprise Value | $611.42M | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.46, down 3.53% on the day, reflecting a bearish technical trend. The company is in a high-growth investment phase, with revenue growing to $36 million in 2026 but reporting significant losses. Recent news highlights a CEO transition and progress in battery manufacturing for defense and consumer electronics, while analyst consensus remains largely positive with a $10.75 price target.
The outlook is bifurcated: strong analyst buy ratings and institutional interest signal long-term potential, but high cash burn, persistent losses, and bearish technical indicators present substantial near-term risks. Investment hinges on successful commercialization and achieving profitability from current expansion efforts.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
